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ABSTRAK 
 
Dalam tahun-tahun kebelakangan ini, perbelanjaan farmaseutikal telah berkembang 
lebih cepat berbanding komponen lain yang berkaitan perbelanjaan penjagaan 
kesihatan. Secara global, tekanan untuk menguruskan perbelanjaan farmaseutikal 
telah membolehkan kerajaan dan organisasi kesihatan bukan kerajaan untuk 
menggalakkan penggunaan ubat-ubatan generik. Pada tahun 2012, perbelanjaan out-
of-poket (OOP) Malaysia terhadap penjagaan kesihatan adalah 79% daripada 
perbelanjaan sektor swasta dan ia adalah dua kali ganda tinggi bagi negara-negara 
berpendapatan tinggi out-of-poket pembayaran (OOPPs), yang purata 37% daripada 
perbelanjaan sektor swasta. Untuk menurunkan OOPPs dan mengurangkan beban 
kewangan terhadap pesakit dalam sektor penjagaan kesihatan swasta, ia amat 
disyorkan untuk menggalakkan penggunaan generik. Di Malaysia, preskripsi ubatan 
generik telah menjadi satu amalan biasa di hospital kerajaan. Walau bagaimanapun, 
trend di hospital perubatan swasta Malaysia keadaannya seolah-olah berbeza. 
Tujuan kajian ini adalah untuk menyiasat pengetahuan pusat perubatan swasta 
Malaysia physicians', dan persepsi berhubung penggantian ubat-ubatan generik bagi 
produk asas. Kaedah rekabentuk penyelidikan campuran telah diguna pakai untuk 
kerja-kerja ini. Di bawah kajian kualitatif, lapan belas pakar perubatan daripada 
bidang perubatan yang berbeza telah ditemuramah. Majoriti pakar memberikan 
pandangan positif tentang penggantian generik tetapi sinis tentang kualiti mereka 
dari segi keberkesanan dan keselamatan bagi beberapa kategori dadah. Doktor lebih 
xvii 
 
suka untuk melihat keputusan biokesetaraan dijalankan oleh pengilang generik dan 
juga mereka lebih suka untuk menghias dengan beberapa kajian farmakodinamik 
berasaskan komuniti kecil. Kajian kuantitatif adalah satu kajian di seluruh negara 
yang melibatkan pakar-pakar perubatan dari pusat perubatan swasta di Malaysia. 
Secara keseluruhan, 263 jawapan diterima daripada hospital berbeza di 
Semenanjung dan Malaysia Timur. Respon yang telah diterima terdiri daripada 
penyertaan dari hospital kecil ke hospital besar dalam rantaian Malaysia. Pelbagai 
persatuan yang ketara telah diperhatikan mengikut butir-butir demografi dan 
pengetahuan dan persepsi doktor mengenai generik. Selanjutnya, kajian intervensi 
pendidikan telah dijalankan untuk menilai kesan ke atas pengetahuan dan persepsi 
doktor tarhadap ubat-ubatan generik. Terdapat sedikit peningkatan dalam 
pengetahuan diperhatikan selepas intervensi, yang disokong oleh pelbagai kajian, 
memastikan perubahan dalam tingkah laku, setiap kali pengetahuan mengenai 
generik telah disediakan. Kejayaan generik di pusat-pusat perubatan swasta di 
Malaysia bergantung kepada perubahan persepsi doktor mengenai ubat-ubatan 
generik. Selain pelaksanaan dasar penggunaan ubat generik untuk hospital swasta di 
Malaysia, ini juga boleh dicapai melalui pembaikan dalam pemasaran dan promosi 
produk generik yang lebih baik. Para doktor yang berkhidmat di hospital-hospital 
awam di Malaysia mungkin mempunyai pemahaman yang lebih baik mengenai 
ubat-ubatan generik, daripada mereka yang menjalankan amalan perubatan di sektor 
swasta, kerana kebanyakan ubat-ubatan yang diberi oleh hospital kerajaan adalah 
generik. Dalam sektor swasta, maklumat akademik boleh membantu meningkatkan 
pengetahuan doktor mengenai ubat-ubatan generik.  
 
 
xviii 
 
GENERIC MEDICINES: ASSESSMENT OF THE KNOWLEDGE AND 
PERCEPTIONS OF MEDICAL SPECIALISTS AND GENERAL 
PRACTITIONERS IN MALAYSIA 
 
 
 
 
ABSTRACT 
 
In recent years, pharmaceutical expenditure has grown faster than many of the other 
components of healthcare spending. Globally, pressure to manage pharmaceutical 
spending has led governments and non-governmental health organizations to 
promote the use of generic drugs. In 2012, Malaysia’s out-of-pocket (OOP) 
expenditure on healthcare was 79% of private sector spending and it was twice the 
high income countries out-of-pocket payments (OOPPs), which average at 37% of 
private sector expenses. To bring down the OOPPs and reduce financial burden on 
patients in private healthcare sector, it is highly recommended to promote the use of 
generics. In Malaysia, generic drug prescribing has become a common practice in 
public hospitals. However, the trend in private medical centres of Malaysia seems to 
be different. The aim of this study was to investigate Malaysian private medical 
centers physicians´ knowledge, and perceptions regarding substituting generic 
medications for originator products. Mix methods research design was adopted for 
this work. Under qualitative study, eighteen medical specialists from different 
medical fields were interviewed. The majority of specialists were positive about 
generic substitution but cynical about their quality in terms of efficacy and safety for 
some drug categories. Physicians preferred to see the results of bioequivalence 
conducted by generic manufacturers and also preferred them to garnish it with some 
small scale community based pharmacodynamic studies. The quantitative study was 
xix 
 
a nationwide survey involving physicians from private medical centres in Malaysia. 
In total, 263 responses were received from different hospitals of Peninsula and East 
Malaysia. The responses received comprised of participation from small to big 
hospitals chains of Malaysia. Various significant associations were observed among 
physicians´ demographic particulars and their knowledge and perceptions about 
generics. Further, an educational interventional study was carried out to evaluate the 
impact on the knowledge and the perceptions of physicians towards generic 
medicines. A slight improvement in knowledge was observed after the intervention, 
which was supported by various studies, assuring a change in behaviour, whenever 
the knowledge about generics was provided. The success of generics in private 
medical centres in Malaysia depends on changing the perceptions of these 
physicians about generic drugs. In addition to implementation of generic drug usage 
policy for private hospitals in Malaysia, this can also be achieved through improved 
marketing and promotion of generic products. The doctors serving in the public 
hospitals in Malaysia might have a better understanding about generic medications, 
than those who are practising in the private sector, since most of the medications 
dispensed by government hospitals are generics. In the private sector, academic 
detailing can help to improve the knowledge of physicians about generic medicines.  
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CHAPTER ONE: GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 Background 
 
The expenditure on healthcare is steadily increasing in many countries around the 
globe. The World Health Organization (WHO) reported that 5.3 trillion dollars were 
spent on healthcare in 2007, which amounted to a sum of 6.5 trillion dollars in a 
recent fact sheet published by the agency (Xu, et al., 2010; WHO, 2012a). Although 
higher health expenditures cannot necessarily be linked with better health outcomes, 
a minimum level of resources are required for a healthcare system to fulfil its vital 
functions adequately. Moreover, with the increment in lifestyle diseases, such as 
hypertension, cardiovascular (CVS) diseases, cancer, and diabetes etc., national 
healthcare costs are increasing noticeably. In recent years, it has been reported that 
pharmaceutical expenditure is growing faster than many of the other components of 
healthcare spending (Henriksson, et al., 1999; Schneeweiss, et al., 2002; Ess, et al., 
2003; Thorpe, K. E., 2005; Zuvekas, et al., 2007; Coma, et al., 2009; Leng, et al., 
2011; Godman, et al., 2012a; Hoffman, et al., 2012; Hermansyah, A., 2013; 
Hoffman, et al., 2013). In the United States of America (USA), total spending on 
medicines in 2010 was $307 billion (bn), an increase of around $60bn since 2005 and 
$135bn since 2001 (Figure 1.1).  
 
Across Europe, healthcare is scarcely managing to cover its expenses. The rise in 
pharmaceutical expenditure is typically between 4% and 13% per annum (Heikkilä, 
et al., 2007; Simoens, S., 2009; Sermet, et al., 2010; Vandoros, et al., 2013). This rise 
is similar to the USA in its pace, especially when compared to the growth of other 
parts of healthcare expenditure (Schneeweiss, et al., 2002; Schneeweiss, et al., 2004). 
3 
 
 
 
Figure 1.1 Spending on Medicines in the US (2001-2010) 
[Adapted and Modified from IMS Database, 2012] 
 
 
 
 
The different ways of raising funds to cover healthcare costs are inadequate, but, of 
even greater concern, the costs themselves are set to ascend. According to World 
Bank statistics, public spending on healthcare in the European Union (EU) could 
shoot up from 8% of the gross domestic product (GDP) in 2000 to 14% in 2030 and 
keep on growing beyond that date. The dominant anxiety of the European healthcare 
sector is to discover new ways to balance its budgets and control spending. If that is 
not achieved, the resources to pay for healthcare will soon fall short of demand (The 
Future of Healthcare in Europe, 2011). All European governments are facing the 
same basic challenge: how to fund their own health-care systems without demanding 
too many sacrifices from the public. A survey conducted in 6 European healthcare 
systems: Switzerland, France, Germany, Italy, Spain and United Kingdom, reveals 
that overall healthcare expenditure has grown on average by about 80% in these 
countries since 1990, while the GDP of the group has grown by only about 25% 
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(Beyer, et al., 2007). This divergence is expected to continue during the coming 
decades (Figure 1.2).  
 
 
 
Figure 1.2 Healthcare Expenditure will Continue to Outpace GDP and Wages  
[Adapted and Modified from Beyer, et al., 2007] 
 
 
 
 
In the lower and middle income countries (LMICs), this expenditure ranges from 
20% - 60% of the total spending on healthcare (Cameron, et al., 2009; Godman, et 
al., 2010a). In these countries, patented medicines generally cost considerably higher 
than their generic counter parts, and by example, they can go up 10 fold (WHO, 
2010a; Cameron, et al., 2012; GaBI Online, 2014). Overall, insurance coverage in 
the LMICs remains poor and many schemes do not cover expenses on medicines. 
Hence, medicines are still mainly purchased through out-of-pocket payments 
(OOPPs) in the private sector. Globally, pressure to manage pharmaceutical spending 
has led governments and non-governmental health organizations to promote the use 
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of generic drugs (De Joncheere, et al., 2002; Simoens, et al., 2006; Simoens, S., 
2007; Araszkiewicz, et al., 2008; Sermet, et al., 2010; Godman, et al., 2012b). 
European health authorities, and health insurance companies, have instigated a 
number of reforms and initiatives in recent years to deal with this unsustainable 
growth. Among the many efforts made by them include a focus on the policies 
surrounding generics, to result in providing high quality treatment at lower prices, 
with considerable savings (Seeley, E. 2008; Seeley, et al., 2008; Figueiras, et al., 
2009; Ministry of Health, Labour and Welfare of Japan, 2012).  
 
 
1.2 Generic Medicines 
 
A generic medicine can be defined in different ways (Birkett, D. J., 2003; Davit, et 
al., 2013; Dunne, et al., 2013). However, the term is easy to understand as defined by 
the WHO as "a pharmaceutical product, usually intended to be interchangeable with 
an innovator product, which is manufactured without a license from the innovator 
company and is marketed after the expiry date of the patent or other exclusive rights" 
(WHO, 2012b). The United States Food and Drug Administration (USFDA) define a 
generic drug product as "a drug product which is comparable to a reference (brand) 
listed drug product in dosage form, strength, route of administration, quality, 
performance characteristics, and intended use". Before registration, similar to all 
medicinal products including originator, generic drug products must pass through a 
rigorous registration process and stringent requirements to ensure their quality, safety 
and efficacy (USFDA, 2012).  
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In addition to these controls, the concept of bioequivalence is an essential 
requirement for any generic registration in many countries including Malaysia 
(Galgatte, et al., 2013). A bioequivalence study is performed to demonstrate a 
clinical equivalence between a generic product and its reference drug product to 
allow a bridging with the clinical studies conducted on the originator product. Hence, 
a repetition of preclinical or clinical studies is not required (European Medicines 
Agency, [EMA], 2010). A generic drug is expected to have the same clinical effect 
i.e. therapeutically equivalent and have a similar safety profile as the branded 
product when administered under the conditions specified in the labelling. Hence, 
generic drugs can be substituted for originator products by physicians and 
pharmacists (Levinson, D. R., 2008). Generic drugs are marketed under a non-
proprietary or approved name rather than a proprietary or brand name. Generic drugs 
are as effective as branded drugs and are much more economical than originator 
brands (Matin, Y., 1999; Simoens, et al., 2006; Shafie, et al., 2008; WHO, 2011; 
Vogler, S., 2012a; European Generic Medicines Association [EGA], 2013a). Generic 
medicines are available as a standard therapy for many acute and chronic diseases 
(Sheppard, A., 2011; EGA, 2013a). 
 
The Hatch-Waxman Act (1984) allows the entry of generic drugs into the market for 
trade, without conducting the expensive clinical trials, unlike their originator 
counterparts (Lewek, et al., 2010; Davit, et al., 2009; Bera, et al., 2012; Perkins, et 
al). Hence, generic development costs are much lower; furthermore, they are being 
sold at a lower price when compared to originator brands. Generic drug 
manufacturers also have to follow similar strict quality standards with respect to 
identity, strength, quality, purity and potency. However, some variability can and 
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does occur during manufacturing, for both the originator and the generic 
products. When a drug product, generic or referenced, is mass-produced, very small 
variations in purity, size, strength, and other parameters are permitted. The USFDA 
limits the amount of variability that is acceptable. Both generic and branded products 
are being manufactured under similar cGMP conditions as those required for the 
innovator companies. All generic manufacturing, packaging, and testing sites, must 
pass the same quality standards as those of the branded drugs, and the generic 
products must meet the same specifications as any brand name product. In fact, many 
generic drugs are made in the same manufacturing plants as the brand name drug 
products. Hence, these low priced generics do not essentially construe to be of a 
lower quality. Generally, generics do not spend on costly advertising, marketing, and 
promotion. In addition, the availability of a single product, from multiple generic 
companies, creates competition in the market place, often resulting in price erosion 
(USFDA, 2012). The USFDA requirements for a bioequivalent generic drug product 
are as follows:  
a. It should have the same active ingredients and strength as the originator 
product. 
b. It should have the same dosage form and route of administration.  
c. It should be bioequivalent i.e. the same amount of the drug should be 
delivered in the same amount of time as that of the reference product.  
d. It should have the same labelling except for the name of the medication. 
e. It should have a documented chemistry, manufacturing steps, and quality 
control measures. The raw materials and finished product specifications 
should meet the United States Pharmacopoeia specifications.  
f. The potency and the shelf-life should be comparable to the reference product. 
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g. The facilities used to manufacture, process, test, package and label the 
generic product should meet good manufacturing practices (GMP). 
 
Thus, generics offer a simple and important solution to these expenditure issues, 
resulting in drug affordability, and the containment of pharmaceutical costs, since the 
price of medicines is a major component of healthcare costs (King, et al., 2002; 
Dukes, et al., 2003; Wallack, et al., 2004; Hassali, et al., 2009a; Godman, et al., 
2010b; Hassali, et al., 2010; Simoens, S., 2010; Doloresco, et al., 2011; Al-Tamimi, 
et al., 2013; Hermansyah, A., 2013). Generic pharmaceuticals have now been cited 
as being a dependable lever to decrease healthcare costs and have continued to 
deliver outstanding savings to many developed countries. Genazzani, et al., stated 
that generic drugs are a major asset to national projects through the reduction of 
pharmaceutical expenses (Genazzani, et al., 2008). Apart from reducing healthcare 
costs, generic medication benefits include the reduction of a patient´s out-of-pocket 
costs, and most importantly, to an increased adherence to the treatment regime 
(Shrank, et al., 2006; Shrank, et al., 2009a; Brems, et al., 2011; Iizuka, et al., 2011). 
With the use of generics, healthcare systems can save substantial amount of money 
which can be utilized to pay for more expensive patented and new innovative 
products that are required to treat some diseases where generics are not available 
(EGA, 2007). The savings from generics can also be utilized by policy makers or 
government to finance the research and development (R&D) and reimbursement of 
newer, expensive innovative medicines (Simoens, et al., 2006). 
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The advantages of generic medications can be listed as below: 
a. Reduction of the overall treatment cost for patients, resulting in the 
affordability and the containment of healthcare costs for governments. 
b. Increased adherence to therapy due to lower medicine costs. 
c. Stimulates innovation and the development of new drugs. 
d. Creates access to essential medicines and the continuity of supply. 
e. Economic development and employment. 
 
Despite the above advantages of generic medicines, their use worldwide is lacking 
(Kirking, et al., 2001). The World Health Report (Chisholm, et al., 2010) has 
identified the following ten leading causes for health system inefficiency: 
a. Medicines - the use of sub standard medicine and counterfeits 
b. Medicines - inappropriate and ineffective use 
c. Medicines - underuse of generics  
d. Healthcare products & services - overuse 
e. Health workers - inappropriate or costly staff mix 
f. Healthcare services - inappropriate hospital admissions and length of stay 
g. Healthcare services - inappropriate hospital size 
h. Healthcare services - medical errors and suboptimal quality of care 
i. Health system leakages - waste, corruption & fraud 
j. Health interventions - inefficient strategies  
 
Under use of generics was listed as one of the main reasons for healthcare system 
inefficiency.  
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Over the period 2003 to 2012, the USA has saved more than $1.2 trillion from the 
healthcare system by using generics. In 2012 itself, the U. S. health system has saved 
$217bn, up from $188bn in 2011, due to the usage of generic medicines (Johnson, L. 
A., 2012; Generic Pharmaceutical Association, 2013). In 2012, savings, only from 
newer generic products (entering the market in the past 10 years), represent more 
than half of the total savings; which means that the use of generics in newer drugs 
will result in an exponential growth in savings (Figure 1.3).   
 
 
 
Figure 1.3 Generics Savings over the Course of Time in the USA 
[Adapted from the Generic Pharmaceutical Association, GPhA, USA] 
 
 
 
 
In the US, generics account for approximately 75% of prescriptions, and this only 
incurs 13% of the total cost of newer, innovative, and generally more expensive 
medications (Kohl, et al., 2007). In Europe, it has been estimated that the use of 
generics is contributing almost €30bn every year to the healthcare system (Sheppard 
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A., 2011). Figure 1.4 depicts the market share of generics which differs a lot among 
the different European countries (Vogler S., 2012b).   
 
 
 
Figure 1.4 Generics Market Share of the Outpatient Market in the EU 
 (% Volume) [Adapted from Vogler S., 2012b] 
 
 
 
 
The study conducted by Vogler, (2012b) in 16 European countries to discover the 
price differences between the originators and generics, for a selected basket of 
molecules, showed that an investment in generics tends to pay off (Vogler, S., 
2012b). As per a recent WHO report, in the private sector of 17 countries, an average 
of 9% - 89% could be saved, by individual medicines, incurring a switch from the 
originator brand to the lowest priced generic equivalent (WHO, 2010a; Brems, et al., 
2011; Kaplan, et al., 2012). In 2006, generics accounted for 42% of dispensed packs 
among 27 countries across Europe, but this cost was only 18% of the total 
pharmaceutical expenditure (Simoens, S., 2008a). 
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However, in order to get the maximum benefits from generics, it is really important 
to ensure that their availability, and immediate market entry, follows the patent 
expiration of the originator (Kanavos, et al., 2008; Fatokun, et al., 2011; Sheppard, 
A., 2011). The objective of generic medicines can be lost, or the results can be 
devastated, by a delayed or hindered entry into the market (Kesselheim, et al., 2006). 
In a study conducted by the European Commission (EC), it was estimated that almost 
€3bn was lost in 27 member countries, due to the delayed entry of generic versions 
of the top selling products between 2000 and 2007 (EC, 2009a).  
 
Globally, governments across many countries have taken various initiatives to bring 
down their healthcare costs, which has led to lower reimbursed prices for generics 
and originators, as well as interchangeable brands, within the pharmacological or 
therapeutic classes (Godman, et al., 2008; Godman, et al., 2009a; Ferner, et al., 2010; 
McGinn, et al., 2010; Godman, et al., 2012a). The dispensing of generics was seen as 
a standard treatment, and this was planned through encouraging or mandating 
pharmacists, to substitute less expensive generic products, in place of the more 
expensive originators, wherever relevant, unless prohibited by physicians or the 
health authorities (Figueiras, et al., 2008; Seeley, et al., 2008; Simoens, S., 2008a). 
Preferential co-payment policies for generics in the US, among the insured 
population and seniors, have also resulted in a high utilisation of generics. As a 
result, generics account for approximately two thirds of prescriptions, but only 13% 
of costs (Kohl, et al., 2007; Shrank, et al., 2009a). Similar situations also occur in 
Asia. As an example, physicians working in government hospitals in Indonesia will 
soon be required to only prescribe generic drugs, unless there are no generic 
alternatives available (Bland, B., 2010). 
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1.2.1 Overview of Generic Drug Product Development Processes 
 
The above brief discussion about generics describes a situation whereby generic 
medication refers to products that are no longer under patent protection. The entry of 
a generic drug product, following the patent expiration of originator, begins with the 
development of the generic drug product (Prasnikar, et al., 2006; Lionberger, R. A., 
2008; Genazzani, et al., 2008). Different markets understand and use the term 
¨generic drug¨ or ¨generic medicine¨, however, it is commonly understood to be as 
per the definition provided by the WHO to mean a pharmaceutical product which is: 
a. usually intended to be interchangeable with an innovator product 
b. manufactured without a license from the originator company, and 
c. marketed after the expiration date of the patent or other exclusive rights 
(Generic drugs, WHO). 
 
Prasnikar, et al., explained that the generic development process initiation completes 
the manufacturing with a market entry of the product and is classified into 6 phases: 
phase 0 (generation of an idea), phase 1 (preliminary assessment), phase 2 
(laboratory development), phase 3 (development of the technology), phase 4 (product 
registration), phase 5 (market launch).  
 
Phase 0 represents the selection of the probable generic candidates based upon many 
factors. Generally, large scale generic pharmaceutical companies will have a 
dedicated expert team, which will propose a list of potential generic molecules every 
year, as a proposal to initiate the next phase of activities (Prasnikar, et al., 2006).    
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Phase 1 is a preliminary assessment phase, where drug molecules are assessed 
roughly for their market potential, patent expiry, complexities, the expenses 
involved, budgets, regulatory and intellectual property concerns, R&D and 
regulatory strategies, production feasibility and other commercial factors. This phase 
is the ‘desk research’ stage, involving all relevant documentation about the potential 
drug molecule, prior to the initiation of any practical activities in a laboratory (WHO, 
2011). A risk based analysis is also conducted in order to introduce the new molecule 
in the development pipeline. 
 
Phase 2 starts in the development laboratory, with experimental work, which 
includes pre-formulation studies, formulation development, analytical method 
development, innovator characterisation, comparative dissolution studies, accelerated 
stability study work, pilot bioequivalence, and primary packaging development 
studies. At this stage, the scale up from the laboratorial to the semi-industrial scale is 
achieved (Prasnikar, et al., 2006; WHO, 2011). 
 
Phase 3 is the process or technology development phase. This phase includes the 
transference of product technology, to industry measurement, and the preparation of 
registration documentation. It includes clinical studies, toxicological studies, 
bioequivalence studies, and the completion of stability studies. This phase ends with 
the manufacturing of 3 registration or submission batches (Prasnikar, et al., 2006).  
 
Phase 4 is the registration of the product with a regulatory agency. The manufacturer 
files all of the documentation related to the product in a dossier, and replies to any 
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queries if any are raised by the regulatory agency during the course of the evaluation. 
This phase aims for obtaining marketing authorisation (Prasnikar, et al., 2006). 
 
Phase 5 is related to activities to be completed for the market launch of the product, 
which includes a launch requirement calculation, the ordering of raw materials and 
packaging materials, toolings etc., and ends with a final launch of the product 
(Prasnikar, et al., 2006). 
 
As discussed earlier, generic drug product related registrations do not involve pre-
clinical and clinical studies as required for the originator product. Alternatively, 
generics have to go through bioequivalence studies only, which are much cheaper 
than the clinical trials that are undertaken by the originators.  
 
Figure 1.5 depicts that the main reason for generics being cheaper products is 
primarily due to their much lower investments when they are compared to the 
innovator products (Dunne, et al., 2013). However, the market price of a generic 
product can be considerably driven by the end-user and the prescription perception, 
local regulations, and reimbursement models (Simoens, S., 2007). Keeping in view 
the manufacturing costs, it should probably not differ significantly, as they (the 
generic and originator products) are both manufactured under the same standards, 
conditions, and the regulations in force as stated by the regulatory authorities. It 
should be noted that an originator product, can turn into a generic product, when the 
patent has expired, and this is very common these days. Since, the branded product 
becomes open to generic competition, after the patent expiry, and noticeable price 
erosions can be observed (Birkett, D. J., 2003).  
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Figure 1.5 Schematic of the Drug Development Process 
 [Adapted from Dunne, et al., 2013]  
 
 
 
 
1.2.2 Are Generics Really the Same as the Originator Products? 
 
There have been, although, concerns with the effectiveness and the safety of generics 
(Himmel, et al., 2005; Kjoenniksen, et al., 2006; Heikkilä, et al,. 2007; Kanavos, P., 
2008; Simoens, S., 2008b; Figueiras, et al., 2009; Tsiantou, et al., 2009; Shrank, et 
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al., 2009a; Shrank, et al., 2009b; Chua, et al., 2010; Ferner, et al., 2010; McCartney, 
M., 2010; Sermet, et al., 2010), with some originator companies questioning the 
quality of generics, as part of their marketing strategies, to reduce the post-patent 
erosion of lost sales (EC, 2009b). However, concerns regarding generics generally 
only apply to a minority of situations (Kjoenniksen, et al., 2006; Shrank, et al., 
2009a; Tsiantou, et al., 2009). There have been a substantial number of clinical 
studies conducted comparing a generic product with a reference product. Most of 
these studies have demonstrated the therapeutic equivalency between the generic and 
the branded drug product. In a recent review article, researchers reported the clinical 
data of 47 studies, which compared generic and reference products, for the treatment 
of heart and artery disease. These studies included some of the most frequently used 
medications that are globally available, like beta-blockers, diuretics, statins, and 
warfarin. These findings suggested that there is no evidence of a superiority of 
branded products, when compared to generic drugs, in measured clinical outcomes 
conducted in these studies (Kesselheim, et al., 2008).  
 
In another study, 428 patients underwent implantation with a drug-eluting stent 
(DES) for coronary artery disease and were enrolled and then completed >1 year of 
clinical follow-up. Patients were divided into the following 2 groups, based on the 
treatment formulation, Platless® (test formulation, n=211), or Plavix® (reference 
formulation, n=217). The incidence of 1-year major adverse CVS, and 
cerebrovascular events (MACCEs), and stent thrombosis, were retrospectively 
reviewed. The result of the study proved that the two preparations of Clopidogrel 
showed similar rates of MACCEs (Park, et al., 2012). 
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Another multicenter study, which assessed the efficacy of a generic form of 
Atorvastatin in 119 patients, showed that Low Density Lipoprotein (LDL)-
Cholesterol was reduced by 36.6% at four weeks and by 37.5% at eight weeks from 
the baseline. Total cholesterol and triglycerides were significantly reduced. There 
were no serious drug-related adverse events. It was concluded that the generic 
product Atorvastatin was safe and effective in the treatment of primary 
hypercholesterolemia (Punithavathi, et al., 2009). 
 
Hence, there are many studies available, to prove this equivalency between generic 
and branded medicines. However, in spite of these studies, some physicians are 
concerned, because the bioequivalence studies, that predicate generics to be the 
equivalent, are not made public. They also have no access to find out about the 
differences in fillers, and other additives, which might change the rates of release. So 
it comes as no surprise that only 12 of 43 medical journal commentaries, on the 
subject of generic vs. brand medicines, encouraged the use of generics (Wegmann, J., 
2010). Various reasons have been identified by researchers about the under 
utilisation of generics. Some physicians, pharmacists, and consumers, have expressed 
that bioequivalent generics, and branded medicines, may not be equivalent in their 
effects on various clinical parameters, including physiological measures, such as 
heart rate, or blood pressure, on important laboratory measurements, and various 
outcomes, such as health system utilisation, or mortality (Gaither, et al., 2001; 
Shrank, et al., 2009a). Narrow Therapeutic Index (NTI) drugs are of particular 
concern, where minor differences in plasma levels, can be less effective, or lead to 
toxicity (Banahan, et al., 1998). Originators have suggested that generics may be less 
effective or/and less safe than their branded counterparts. Anecdotes have appeared 
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in the lay press raising doubts about the efficacy and the safety of certain generic 
drugs (Saul, et al., 2007; Beck, M., 2008; Rockoff, J., 2008). There have also been 
concerns related to confusion, when patients are dispensed multiple branded 
generics, each with different names and appearance, which can potentially lead to 
medical errors (Godman, et al., 2009b; Decollogny, et al; 2011; Kesselheim, et al., 
2014; Oyetunde, et al., 2014).  
 
1.2.2.1 Generic Substitution  
 
Generic medicines offer same health outcomes as they are clinically equivalent 
interchangeable medicines with originator products, but at a much cheaper cost 
(Godman, et al., 2010b). Generics are considered to be a cost-effective, first line or 
standard therapy for many diseases and conditions, such as hypertension, diabetes, 
hyperlipidaemia, hypercholesterolaemia, allergies, depression, gastrointestinal 
disorders, osteoporosis, infections, skin diseases etc. (Sheppard, A., 2011; EGA, 
2013b). However, there has been concerned raised with some NTI drugs, specifically 
due to switching or substituting them but not prescribing or dispensing them for the 
first time, currently there is no evidence of inferiority of generics. Currently, generic 
medicines are promoted as an integral part of healthcare systems (Al-Tamimi, et al., 
2013), not only due to their affordability but also for sustainability of healthcare 
systems (Alrasheedy, et al., 2013). In order to promote generic medications, generic 
substitution (GS) and generic prescribing has been adopted by many healthcare 
systems (Vogler, S., 2012b). GS can be defined as an act of dispensing an equivalent 
generic medicine when an originator brand is prescribed (i.e. switching the patient 
from an originator product to an equivalent generic product), while generic 
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prescribing is defined as prescribing by the approved international non-proprietary 
name (INN) of the medicines (Ferner, et al., 2010). There are two aspects to consider 
regarding the use of generics: the ‘prescribability’ or ‘dispensability’ of generics (i.e. 
prescribing or dispensing generics for the first or initial patient prescription) and the 
‘switchability’ or substitution (Rani, et al., 2004; Thiessen, J. J., 2005).  
 
During a GS, there are many aspects that must be taken into consideration. The 
physician’s attitude towards GS is most often related to their general prescribing 
behaviour, their perception of therapeutic efficacy, their beliefs about generics, and 
their previous experience using generic alternatives, including any negative effects. 
Pharmacists may consider other kinds of issues like regulatory matters, the 
therapeutic class of the drug, the cost, and the bioequivalence information, when 
dispensing generic medication, as well as a patient’s medical and medication history, 
together with their acceptance to a change of brand. Also one need to consider 
patient’s preference, their consent, prescriber’s approval (if needed), patient’s 
understanding of the difference between the medicine brands to prevent any 
confusion due to brand changing (especially for elderly patients), consistency in the 
selection of the brand, especially for chronic and long-term therapy, the assessment 
of allergy history to any excipient, whether the new brand needs different 
instructions to be understood, and the patient’s familiarity with the brand (e.g. 
metered-dose dry-powder inhalers etc.) (International Society of Drug Bulletins, 
2006; National Prescribing Service Limited, 2006; National Prescribing Service 
Limited, 2007; Duerden, et al., 2010). A patient’s concerns can be the drug’s 
efficacy, their overall satisfaction, the side effects, its appearance, in addition to their 
willingness to take medication, and every concern about managing their health 
21 
 
condition. Old aged patients do generally not prefer a change in their medicine or its 
appearance (Banahan, et al., 1997; Suh, D. C., 1999; Mott, et al., 2002; Kjoenniksen, 
et al., 2006; Best Practice Journal, 2007).  
 
In addition, it is needed to educate patients about quality, safety, efficacy of generics 
and their bioequivalence, the similarities and differences between them against the 
originator product. The issues related with the usage of generics can be categorized 
with respect to the user as: 
 
i. Consumers: Major barriers to acceptance include: 
a. Preference for a doctor’s prescribed brand of medicine, 
b. Concern over the safety and the efficacy of generic medicine, 
c. Concern about the adverse effects from generic brands, and the confusion 
that may arise from different brands of the same medicine. 
 
ii. Prescribers/Pharmacists: Major barriers to acceptance include: 
a. A possibility of patient confusion and a low level of confidence with 
generic medicine. 
b. Loyalty to the companies involved in R&D. 
c. A lack of knowledge on the issues surrounding bioequivalence testing for 
generic medicines. 
 
Therefore, healthcare professionals need to assess the suitability of GS based on their 
professional judgment (USFDA, 2014). However, it is more important to note that 
the generic product must be bioequivalent and therapeutically equivalent to the 
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originator while GS. Thus, unlike other factors that need to be considered when 
performing GS, therapeutic equivalence should be based on scientific evidence rather 
than the professional judgement of individual healthcare professionals, as GS is not 
appropriate for some medicines (Duerden, et al., 2010; Ferner, et al., 2010; Lewek, et 
al., 2010; Holmes, et al., 2011). For example, NTI drugs such as antiarrhythmic 
drugs (e.g. digoxin), anti-epileptic drugs (e.g. carbamazepine), anticoagulant drugs 
(e.g. warfarin), and immunosuppressants (e.g. tacrolimus). Other examples include 
solid oral modified-release dosage forms of drugs like carbamazepine, diltiazem, 
morphine and oxycodone etc., medicines containing more than one active ingredient 
(e.g. oral contraceptives, antacid preparations containing simethicone), different 
products of the same active ingredient that have different licensed indications [e.g. 
sildenafil (Viagra® or Revatio®], and products using different salts to form the 
active ingredients (e.g. nortriptyline) (Duerden, et al., 2010; Ferner, et al., 2010; 
Lewek, et al., 2010; Holmes, et al., 2011). 
 
To avoid such situations, many countries have implemented regulatory guidelines to 
ensure that prescribing and substitution of generic products are appropriate. One such 
example is the Approved Drug Products with Therapeutic Equivalence Evaluations, 
commonly known as the ‘Orange Book’, which is a useful guide for pharmacists and 
other healthcare professionals with regards to therapeutic equivalence and approved 
generic products in the United States (USFDA, 2014). In Orange book, products that 
are therapeutically equivalent, where there is adequate evidence supporting 
bioequivalence, are designated with a code ‘A’, and products that are not 
therapeutically equivalent, where there is no adequate evidence supporting 
bioequivalence, are designated with a code ‘B’.  
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Another example is from Australia, the Schedule of Pharmaceutical Benefits (PBS), 
which is a useful guide for healthcare professionals and consumers regarding 
therapeutic equivalence between medicines (Department of Health and Ageing - 
Australia, 2007; Department of Health and Ageing - Australia, 2013). In this 
schedule, ‘a’ precedes the names of therapeutically equivalent and interchangeable 
medicine brands, whereas ‘b’ is attached to brands of medicines that are equivalent 
to the original brand but there is no evidence of equivalency between them. For other 
medicines not marked with ‘a’ or ‘b’, their therapeutic equivalence is not known; 
hence, caution should be exercised when GS is done. British National Formulary of 
United Kingdom is a useful tool for healthcare professionals when GS is not suitable 
for some medicines (Duerden, et al., 2010; Ferner, et al., 2010; Joint Formulary 
Committee, 2011). The Royal Dutch Pharmacists Association (KNMP) of The 
Netherlands has produced a professional guideline for community pharmacists 
regarding GS. This guideline provides principles and guidance to community 
pharmacists to perform GS appropriately. It also addresses the issue of NTI drugs 
and other drugs for which GS is not appropriate. Furthermore, it addresses random 
substitution and the general considerations and factors that need to be taken into 
account, such as the factors related to patients, prescribers and legal issues (Grandia, 
et al., 2012; KNMP, 2012). 
 
There is ample evidence in literature for the necessity of having a formulary of 
interchangeable medicines to facilitate appropriate GS (Chong, et al., 2010a; Chua, et 
al., 2010; Johnston, et al., 2011; Hassali, et al., 2012a). Johnston, et al., (2011) 
recommended that evidence regarding therapeutic equivalence should be made 
available to the public and that best practice guidelines are required for GS 
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(Johnston, et al., 2011). Furthermore, Hassali, et al., (2012a) concluded that a 
formulary of interchangeable medicines must be developed to promote responsible 
GS. The formulary should also contain the list of the products that are not suitable 
for GS. Such a formulary would help both pharmacists and prescribers to assess the 
generic equivalence of the products offered as alternative substitutes (Hassali, et al., 
2012a). In conclusion, it is essential to have a formulary of interchangeable products 
to guide responsible GS, to help healthcare professionals to be more confident when 
providing GS and to avoid situations where GS is inappropriate. 
 
Many studies are available in the literature promoting the use of generics (Amit, et 
al., 2004; Araszkiewicz, et al., 2008; Kesselheim, et al., 2008; Davit, et al., 2009; 
Punithavathi, et al., 2009; Kesselheim, et al., 2010; Park, et al., 2012), and are also 
reporting positively about the safety and the efficacy associated with the switching of 
products (Alessi-Severini, et al., 2006; Paton, C., 2006). On the contrary, there have 
been reports about a patient’s concerns relating to generic medicine. These studies 
range from the qualitative assessment of the perceptions in specific patient 
populations (Bulsara, et al., 2010), to general consumer knowledge (Hassali, et al., 
2009a; Figueiras, et al., 2010), versus the knowledge of professionals, which 
includes pharmacists and physicians (Babar, et al., 2011; Qunital, et al., 2012). Many 
of these studies focus on the influence of a relatively cheaper price of any 
prescriptions and the use of generic products (Heikkilä, et al., 2011a; Heikkilä, et al., 
2011b; Heikkilä, et al., 2012). On the other hand, there have been many studies 
depicting the facts that consumers feel that a generic drug product is less effective 
when compared to the originator’s medicine. There have also been studies reporting 
that the consumer responded well and then advanced in treatment when switched 
